Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/05/033626
CTRI/2021/05/033626
Completed
未知

A prospective case control interventional study to assess safety and efficacy of proprietary Ayurvedic medicine Tab. â??CoReachâ?? in non-critical and antiviral naïve COVID-19 positive patients

Questt Clinicals and Ayurceuricals Pvt Ltd0 sites106 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Questt Clinicals and Ayurceuricals Pvt Ltd
Enrollment
106
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
July 23, 2021
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Questt Clinicals and Ayurceuricals Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • •I. Patients with laboratory confirmation of infection with SARS CoV\-2 by positive RT\-PCR or Rapid Antigen Test with mild to moderate symptoms (Mild: Upper respiratory tract symptoms (\& or fever) WITHOUT shortness of breath or hypoxia
  • •Moderate: Any one of: 1\. Respiratory rate \> 24/min, breathlessness 2\. SpO2: 90% to \< 93% on room air
  • •Ref: AIIMS ICMR\-COVID\-19 National Task Force)
  • •Patients progressing from moderate to severe grade during treatment will be withdrawn from the study
  • •II. Age \>18 and \< 75 years at the time of signing ICF
  • •III. Voluntarily participation in the clinical trial and agreeing to follow study procedures
  • •IV. Not participating in any other interventional drug clinical studies before completion of the present study
  • •V. Ready to give medical data for assessments

Exclusion Criteria

  • •I. Critical infection, defined as need for invasive ventilator support
  • •II. Inability to intake or tolerate oral medications.
  • •III. Known pregnant or lactating women
  • •IV. Persons with severe primary respiratory disease or other pneumonia
  • •V. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A study to observe and assess the safety and efficacy of Unani regimen in preventing the progression of severity of asymptomatic mild to moderate symptomatic cases.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
CTRI/2020/07/026462Central Council for Research in Unani Medicine CCRUM New Delhi62
Completed
Not Applicable
Prospective, controlled interventional study to determine the benefit of a clinical pharmacist on a German intensive care unitmedication errors
DRKS00013184Gesundheit Nordhessen Holding AG336
Recruiting
Not Applicable
Prospective, controlled intervention study to optimize bowel evacuation and stimulation in extremely premature infantsP07.01P07.02
DRKS00024191Klinik für Neonatologie und allgemeine Pädiatrie Klinikum Kassel54
Completed
Not Applicable
A study to assess the effect of thermal softening of endotracheal tube in reducing post operative sore throatHealth Condition 1: O- Medical and Surgical
CTRI/2022/03/040813RajaRajeswari Medical College and Hospital270
Not yet recruiting
Phase 1
Probiotics to initiate ovulation in women with PolyCystic Ovarian Syndrome (PCOS) and Irritable Bowel Syndrome (IBS)
ACTRN12612001192875niversity of South Australia16